CRISPR Therapeutics AG reports a Schedule 13G filing showing Capital World Investors beneficially owns 4,929,428 shares of Common Stock, equal to 5.1% of the company.
The filing states CWI has sole voting power over 4,897,705 shares and sole dispositive power over 4,929,428 shares. The ownership figure is stated as of 03/31/2026.
Positive
None.
Negative
None.
Insights
Large passive stake reported: CWI holds 5.1% of CRISPR Therapeutics.
Capital World Investors is disclosed as the beneficial owner of 5.1% of Common Stock, representing 4,929,428 shares as of 03/31/2026. The filing shows sole voting power for 4,897,705 shares, indicating centralized voting control within the reported position.
Future filings may show changes in this position; any material shifts would appear in subsequent ownership disclosures. Cash‑flow treatment and trading intent are not stated in the excerpt.
Key Figures
Beneficial ownership:4,929,428 sharesPercent of class:5.1%Shares outstanding:95,985,312 shares+2 more
5 metrics
Beneficial ownership4,929,428 sharesBeneficially owned as stated in Schedule 13G
Percent of class5.1%Percent of 95,985,312 shares outstanding as stated
Shares outstanding95,985,312 sharesShare base used to compute 5.1% (as provided in filing)
Sole voting power4,897,705 sharesSole power to vote or direct the vote
Filing date / effective date03/31/2026 / signed 05/13/2026Reporting date and signature date on Schedule 13G
Key Terms
Beneficially owned, Sole Dispositive Power, Schedule 13G
3 terms
Beneficially ownedregulatory
"CWI is deemed to be the beneficial owner of 4,929,428 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Dispositive Powerregulatory
"Sole power to dispose or to direct the disposition of: 4,929,428"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13Gregulatory
"Item 1. (a) Name of issuer: CRISPR Therapeutics"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CRISPR Therapeutics AG
(Name of Issuer)
Common Stock
(Title of Class of Securities)
H17182108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
H17182108
1
Names of Reporting Persons
Capital World Investors
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,897,705.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,929,428.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,929,428.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CRISPR Therapeutics AG
(b)
Address of issuer's principal executive offices:
Baarerstrasse 14, Zug, ZG 6300, Switzerland
Item 2.
(a)
Name of person filing:
Capital World Investors
(b)
Address or principal business office or, if none, residence:
333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
(c)
Citizenship:
N/A
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
H17182108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4,929,428 **
**Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 4,929,428 shares or 5.1% of the 95,985,312 shares believed to be outstanding.
(b)
Percent of class:
5.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
4,897,705
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
4,929,428
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Capital World Investors
Signature:
Jae Won Chung
Name/Title:
Senior Vice President and Associate General Counsel, Capital Research and Management Company
What stake does Capital World Investors report in CRISPR Therapeutics (CRSP)?
Capital World Investors reports beneficial ownership of 4,929,428 shares, representing 5.1% of Common Stock as of 03/31/2026. The filing lists voting and dispositive powers for those shares.
Does Capital World Investors have voting control over its CRISPR Therapeutics shares?
Yes. The filing states CWI has sole voting power over 4,897,705 shares and sole dispositive power over 4,929,428 shares, per the Schedule 13G disclosure.
How many CRISPR Therapeutics shares were outstanding per the filing?
The Schedule 13G cites a share base of 95,985,312 shares outstanding, which is the denominator used to calculate the 5.1% ownership percentage reported by CWI.
When was the ownership level reported by Capital World Investors effective?
The filing lists the relevant date as 03/31/2026. The Schedule 13G and the signature show the disclosure was signed on 05/13/2026.
Does the Schedule 13G indicate whether these shares were acquired for control or investment?
The filing describes beneficial ownership and voting/dispositive powers only; it does not state the acquisition purpose or trading intent for the reported 4,929,428 shares.
